Archiv
Archiv anzeigen:
bis


Preserving Ovarian Function in Young Women with Breast Cancer

William J. Gradishar, MD reviewing Leonard RCF et al. Ann Oncol 2017 Aug 1

The gonadotropin-releasing hormone agonist goserelin reduced the risk for chemotherapy-induced ovarian insufficiency in premenopausal women with early-stage disease.


Restarting Adjuvant Endocrine Therapy for Breast Cancer

William J. Gradishar, MD reviewing He W et al. J Natl Cancer Inst 2017 Oct 01

Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.


Maintenance Immunotherapy for Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Le Gouill S et al. N Engl J Med 2017 Sep 28

The use of rituximab following consolidation therapy and autologous stem cell transplantation significantly improved patient outcomes.


CAR-T Cell Therapy for Chronic Lymphocytic Leukemia

Michael E. Williams, MD, ScM reviewing Turtle CJ et al. J Clin Oncol 2017 Sep 10

This complex therapeutic modality was highly effective in relapsed CLL patients who failed treatment with ibrutinib.


Azithromycin Increases Mortality After Hematopoietic Stem Cell Transplantation

Daniel Kaul, MD reviewing Bergeron A et al. JAMA 2017 Aug 8

Airflow decline–free survival was worse with azithromycin versus placebo in patients who underwent allogeneic HSCT for a hematologic malignancy.


Recombinant ADAMTS13 for Congenital Thrombotic Thrombocytopenic Purpura

David Green, MD, PhD reviewing Scully M et al. Blood 2017 Sep 14

In a phase I study, recombinant human ADAMTS13 was safe, non-immunogenic, and well tolerated.


Adding Lorazepam to Haloperidol Might Help Alleviate Agitated Delirium in Advanced-Cancer Patients

Thomas L. Schwenk, MD reviewing Hui D et al. JAMA 2017 Sep 19, Pandharipande PP and Ely EW. JAMA 2017 Sep 19

Short-term reductions in agitation were helpful, but other components of delirium need further study.


Transfusions of Fresh vs. Older Blood in Seriously Ill Patients

David Green, MD, PhD reviewing Cooper DJ et al. N Engl J Med 2017 Sep 27

Use of fresh blood does not improve survival for intensive-care patients.


Consolidation Immunotherapy After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2017 Sep 8

Adding durvalumab to standard therapy significantly improved outcomes, but longer follow-up is required.


Ramucirumab for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Petrylak DP et al. Lancet 2017 Sep 12, Bellmunt J. Lancet 2017 Sep 12

Adding the IgG1 monoclonal antibody ramucirumab to docetaxel improved progression-free survival at 5-month follow-up.


Archiv
Seite von 60
Editorial Member Board Empfehlungen

Prof. Dr. med. Beat Thürlimann

Brustzentrum St. Gallen

Liebe Kolleginnen und Kollegen!

Auch die neue «Journal Watch»-Serie von ausgewählten Publikationen gibt Ihnen die Möglichkeit, sich rasch und effizient über wichtige Neuigkeiten zu informieren. Ich habe mich bei der Auswahl auf praxisrelevante Informationen konzentriert: Therapieoptionen und Resistenzmechanismen bei der grossen Gruppe der KRAS-mutierten NSCLC bleiben eine grosse Herausforderung, sowohl wissenschaftlich wie auch klinisch. Das Prostatakarzinom wird ebenso wie das Mammakarzinom nach molekularen Subtypen kategorisiert, in der Absicht, prognostische Gruppen zur Primärbehandlung besser abgrenzen zu können, und um molekulare «targets» zu finden, welche auch systemtherapeutisch angegangen werden können. Im Weiteren gibt es bei der Metastasierung des Prostatakarzinoms auch eine Reihe von neuen Therapiemöglichkeiten mit endokriner Therapie und Chemotherapie. Es geht dabei um den optimalen Gebrauch der neuen Therapien im Verlauf der Krankheit. Zwei Beiträge finden Sie zum onkologischen Dauerbrenner des Antikoagulanzieneinsatzes bei Tumorerkrankungen – eine Reise zwischen Skylla und Charybdis. Ein weiteres Dauerthema ist die Deeskalation bei der heutigen Tumortherapie. Zwei Beispiele sind ausgewählt worden: eine Untersuchung zur Stammzelltransplantation und die Problematik, eine erfolgreich eingesetzte Substanz im Verlauf auch wieder zu stoppen. Schliesslich wird die neue, sehr wirksame Therapie in Form von Pembrolizumab beim refraktären Hodgkin-Lymphom gezeigt: ein entscheidender Fortschritt für die Betroffenen.

Kommentar weiterlesen

Little Benefit to Extensive Breast Cancer Monitoring

William J. Gradishar, MD reviewing Accordino MK et al. J Clin Oncol 2016 Aug 20, Smith KL and Smith TJ. J Clin Oncol 2016 Aug 20

The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.


FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

David H. Ilson, MD, PhD reviewing Enzinger PC et al. J Clin Oncol 2016 Aug 10

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.


Reversing Anticoagulant-Associated Bleeding with Andexanet

David Green, MD, PhD reviewing Connolly SJ et al. N Engl J Med 2016 Aug 30

Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.


Another Tool to Help Breast Cancer Patients Avoid Chemotherapy

William J. Gradishar, MD reviewing Cardoso F et al. N Engl J Med 2016 Aug 25, Hudis CA and Dickler M. N Engl J Med 2016 Aug 25

A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.


Daratumumab for Advanced Light Chain Amyloidosis

David Green, MD, PhD reviewing Sher T et al. Blood 2016 Aug 19

Declines in light chain levels were achieved in heavily pretreated patients.


HER2 a Potential Target in Colorectal Cancer

David H. Ilson, MD, PhD reviewing Sartore-Bianchi A et al. Lancet Oncol 2016 Jun

The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.


Resistance to Anti–PD-1 Therapy in Melanoma Patients

Jeffrey A. Sosman, MD reviewing Zaretsky JM et al. N Engl J Med 2016 Jul 13

Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.


Adjuvant S-1 for Resected Pancreatic Cancer

David H. Ilson, MD, PhD reviewing Uesaka K et al. Lancet 2016 Jun 2, Ko AH et al. Lancet 2016 Jun 2

Overall survival was significantly better with S-1 versus gemcitabine.


Pembrolizumab for Advanced Melanoma

Jeffrey A. Sosman, MD reviewing Ribas A et al. JAMA 2016 Apr 19, Bhatia S and Thompson JA. JAMA 2016 Apr 19

The objective response rate was 33%, and the median duration of response was 28 months.


PD-1 Blockade for Advanced Merkel-Cell Carcinoma

Jeffrey A. Sosman, MD reviewing Nghiem PT et al. N Engl J Med 2016 Apr 19

Pembrolizumab induced frequent and durable responses with manageable toxicity.